{"slug":"ghk","seoKey":"ghk","displayName":"GHK","codes":["GHK","Gly-His-Lys","Tripeptide-1 (INCI, CosIng 59874)"],"synonyms":["copper-free GHK","glycyl-L-histidyl-L-lysine","Tripeptide-1","Tripeptide-1 Acetate (INCI, CosIng 100255)","prezatide","GHK acetate","GHK-F"],"legalClass":"cosmetic","identifiers":{"cas":"49557-75-7","pubchemCid":73587,"unii":"39TG2H631E","inchikey":"MVORZMQFXBLMHM-QWRGUYRKSA-N","drugbankId":"DB11296","wikidataQid":"Q55999876","formula":"C14H24N6O4","molecularWeight":340.38,"sequence":"GHK"},"approvals":[{"market":"US","status":"not_approved","date":"2026-09-23","note":"Not an approved medicine. As a cosmetic ingredient it needs no pre-market approval; the Cosmetic Ingredient Review panel found Tripeptide-1 \"safe in the present practices of use and concentration in cosmetics\" (final report 2014; 0.00002 to 0.001 per cent, 36 products). The NDC directory holds one bulk ingredient listing for prezatide monoacetate (NDC 71052-050, marketing start 2024-07-15) and two over-the-counter topical listings; a listing is a self-registration, not an approval. The FDA safety-risk list (as at 2026-04-22) and the 503A nomination list (as at 2026-05-14) name only GHK-Cu, not copper-free GHK.","source":"https://www.cir-safety.org/sites/default/files/tripep062014final.pdf"},{"market":"EU","status":"not_approved","date":"2026-09-23","note":"Not an authorised medicine: the EMA medicines data set contains no entry for prezatide, glycyl or GHK on 2026-09-23 (control somatropin found). Listed cosmetic ingredient TRIPEPTIDE-1 (CosIng 59874; skin conditioning, skin protecting) with no annex entry and no restriction; the acetate has its own entry (100255). The absence of an annex entry rests on the CosIng data, checked against the control hydroquinone, not on the full text of the cosmetics regulation, which EUR-Lex did not serve (bot challenge).","source":"https://ec.europa.eu/growth/tools-databases/cosing/details/59874"},{"market":"DE","status":"not_approved","date":"2026-09-23","note":"Not an authorised medicine: neither a national nor an EU marketing authorisation. Marketable as a cosmetic under the directly applicable EU cosmetics regulation. A product with a medicinal purpose, such as a solution for injection, would fall under the Medicines Act and be unmarketable without authorisation. Not named in the annex to the Anti-Doping Act. No GHK-specific authority decision was found; the classification is derived.","source":"https://ec.europa.eu/growth/tools-databases/cosing/details/59874"},{"market":"UK","status":"not_approved","date":"2026-09-23","note":"No authorised medicine found: the electronic Medicines Compendium returned no result for \"prezatide\" on 2026-09-23 (control somatropin: 21). The MHRA product database itself could not be evaluated by machine. Cosmetic status not checked separately; the retained version of the EU cosmetics regulation applies.","source":"https://www.medicines.org.uk/emc/search?q=prezatide"},{"market":"AU","status":"not_approved","date":"2026-09-23","note":"No approval found. Not named in the Poisons Standard (June 2026): a full-text search for GHK, glycyl, tripeptide, prezatide, Gly-His and histidyl returned no match, while the controls pralmorelin and BPC were found; copper-free GHK is unscheduled. A product for treatment would still need an ARTG registration; the ARTG itself was not searched, and the industrial chemicals inventory (AICIS) for the cosmetic side could not be retrieved.","source":"https://www.legislation.gov.au/"},{"market":"CA","status":"not_approved","date":"2026-09-23","note":"No authorised medicine: Drug Product Database active-ingredient searches for \"prezatide\", \"glycyl\" and \"tripeptide\" returned nothing on 2026-09-23 (control somatropin: 51). Not on the Cosmetic Ingredient Hotlist (page dated 2025-08-13; control hydroquinone listed); the hotlist was evaluated only through a page summary.","source":"https://health-products.canada.ca/api/drug/activeingredient/?lang=en&type=json&ingredientname=prezatide"},{"market":"CH","status":"not_approved","date":"2026-09-23","note":"No authorised medicine: the Swissmedic list of authorised human medicines (copy of 2026-09-15) contains no match for prezatid, glycyl, tripeptid, GHK or Gly-His (controls Genotropin and Norditropin found). Cosmetic status under the federal ordinance on cosmetic products not checked.","source":"https://www.swissmedic.ch/swissmedic/de/home/services/listen_neu.html"}],"devStage":"preclinical","strongestEvidence":"animal","wada":{"status":"prohibited","section":"S0","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[],"sameAs":["https://pubchem.ncbi.nlm.nih.gov/compound/73587","https://www.wikidata.org/wiki/Q55999876","https://go.drugbank.com/drugs/DB11296"],"lastVerified":"2026-09-24","version":"1.0","published":true,"locale":"en","title":"Copper-free GHK: what the studies show, status and safety","summary":"Copper-free GHK is a tiny peptide the body makes itself, built from three amino acids. As the cosmetic ingredient Tripeptide-1 it is listed in the EU and was judged safe for creams in 2014. As a medicine it is approved nowhere, and injecting it is approved nowhere either. No study in people has ever tested the bare peptide without copper. The human results quoted for it belong to the copper complex GHK-Cu or to a modified molecule. What is shown for copper-free GHK comes from chemistry, cell cultures and rodents.","updated":"2026-09-24","url":"https://mypep.app/peptides/ghk"}